oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Petersdorf and Beeson defined pyrexia of unknown origin (PUO) in 1961. It is defined as:
- A temperature greater than 38.3°C on several occasions.
- Accompanied by more than three weeks of illness.
- Failure to reach a diagnosis after one week of inpatient investigation.
This timing allowed exclusion of patients with protracted but self-limited viral illnesses, giving time for studies to be completed. This has now been modified to include patients who are diagnosed after two outpatient visits or three days in hospital.
Additional categories have now been added including:
- Nosocomial PUO in hospital patients with fever of 38.3°C on several occasions, caused by a process not present or incubating on admission, where initial cultures are negative and diagnosis unknown after three days of investigation.
- Neutropenic PUO includes patients with fever as above with <1 x 109 neutrophils, with initial negative cultures and diagnosis uncertain after three days.
- HIV-associated PUO includes HIV-positive patients with fever as above for four weeks as outpatients or three days as inpatients, with an uncertain diagnosis after three days of investigation, where at least two days have been allowed for cultures to incubate.
Common causes of pyrexia of unknown origin
Most cases are unusual presentations of common diseases - eg, tuberculosis, endocarditis, gallbladder disease and HIV infection, rather than rare or exotic diseases.
- In adults: infections and cancer (25-40% of cases each) account for most PUOs. Autoimmune disorders account for 10-20% of cases.
- In children, at least 50% of cases are due to viral infections. Cancers, autoimmune diseases and miscellaneous conditions make up the remainder.
- There may be no localising symptoms.
- Previous abdominal or pelvic surgery, trauma or history of diverticulosis or peritonitis increase the likelihood of an occult intra-abdominal abscess.
- They are most commonly in the subphrenic space, liver, right lower quadrant, retroperitoneal space or the pelvis in women.
- When dissemination has occurred - eg, in patients who are immunocompromised - the initial presentation is more likely to consist of constitutional symptoms than localising signs. CXR may be normal.
- Urinary tract infections (UTIs) are rare causes. Perinephric abscesses occasionally fail to communicate with the urinary system, resulting in a normal urinalysis.
- Endocarditis is a rare cause of PUO:
- Culture-negative endocarditis is reported in 5-10% of endocarditis cases.
- The HACEK group is responsible for 5-10% of cases of infective endocarditis and is the most common cause of Gram-negative endocarditis among people who do not abuse intravenous drugs:
- This is a group of Gram-negative bacilli - Haemophilus spp., (H. parainfluenzae, H. aphrophilus and H. paraphrophilus), Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens and Kingella spp.
- They are part of the normal oropharyngeal flora, are slow growers and prefer a carbon dioxide-enriched atmosphere.
- Because of their fastidious growth requirements, they have been a frequent cause of culture-negative endocarditis.
- Previous antibiotic therapy is the most frequent reason for negative blood cultures.
- Hepatobiliary infections - eg, cholangitis - can occur without local signs and with only mildly elevated or normal LFTs, especially in the elderly.
- Osteomyelitis usually causes localised pain or discomfort at least sporadically.
- Brucellosis should be considered in patients with persistent fever and a history of contact with cattle, swine, goats or sheep, or patients who consume raw milk products.
- Borrelia recurrentis is transmitted by ticks. It is responsible for causing relapsing fever.
- Other spirochetal diseases that can cause PUO include Spirillum minor (rat-bite fever), Borrelia burgdorferi (Lyme disease) and Treponema pallidum (syphilis).
- Herpes viruses, such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV), can cause prolonged febrile illnesses with constitutional symptoms and no prominent organ manifestations, particularly in the elderly.
- Prolonged febrile episodes are frequent in patients with advanced HIV infection.
- Approximately 75% of the cases are infectious in nature, about 20-25% are due to lymphomas and a small fraction (0-5%) are due to HIV itself.
- Over 80% of patients with AIDS and lymphomas have involvement of extranodal sites - usually the brain.
- Immunosuppression, the use of broad-spectrum antibiotics, the presence of intravascular devices and total parenteral nutrition all predispose people to disseminated fungal infections.
- Toxoplasmosis should be considered in patients who are febrile with lymph node enlargement.
- Trypanosoma, leishmania and amoeba species may rarely cause PUO.
- Coxiella burnetii may cause chronic infections, chronic Q fever or Q fever endocarditis may be identified in patients with a PUO.
- Infection by the causative organism, Chlamydophila psittaci should be considered in a patient with PUO who has a history of contact with birds.
- This should also be considered but is rare.
- Hodgkin's lymphoma and non-Hodgkin's lymphoma may cause PUO.
- Leukaemias may also be responsible.
- Among solid tumours, renal cell carcinoma is most commonly associated with PUO.
- Solid tumours such as adenocarcinomas of the breast, liver, colon or pancreas and liver metastases from any primary site may present with fever.
- Malignant histiocytosis is a rare, rapidly progressive malignant disease.
A wide variety of drugs can cause drug fever:
- The most common are beta-lactam antibiotics, procainamide (now discontinued) and isoniazid. Stopping the drug generally leads to recovery within two days.
- It is usually accompanied by a rash.
Collagen vascular and autoimmune diseases
- Systemic-onset juvenile idiopathic arthritis. High-spiking fevers, nonpruritic rashes, arthralgias and myalgias, pharyngitis and lymphadenopathy typically are present.
- Polyarteritis nodosa (PAN), rheumatoid arthritis and mixed connective-tissue diseases should be considered.
- Giant cell arteritis and also the related polymyalgia rheumatica.
- Polyarteritis nodosa.
- Behçet's disease has also been reported.
Peripheral pulmonary emboli
Peripheral pulmonary emboli and occult thrombophlebitis can cause PUO.
Hyperthyroidism and subacute thyroiditis
- These are the most common endocrine causes of PUO.
- Adrenal insufficiency is a rare but potentially fatal cause of PUO.
Kikuchi's disease is a self-limiting necrotising lymphadenitis. It has been reported as a cause of PUO.
10-15% of patients remain undiagnosed despite extensive investigations and, in 75% of these, the fever resolves spontaneously. In the remainder, other signs and symptoms make the diagnosis clear.
This is a common problem. In western countries, connective tissue diseases, vasculitis syndromes and granulomatous diseases are the most common non-infectious causes. Among these conditions, giant cell arteritis and polymyalgia rheumatica are the most frequent specific diagnosis in the elderly. In younger patients, the most frequent diagnosis is adult-onset Still's disease.
The first step is to confirm temperature by taking it yourself. Look for signs usually accompanying fever - eg, tachycardia, chills. It is very important to take a thorough history:
- Inquire about symptoms from all major systems. Include general complaints - eg, fever, weight loss, night sweats, headaches and rashes.
- Record all complaints, even if not currently present. Previous illnesses, including surgery and psychiatric problems, are important.
- Discuss nutrition, including consumption of dairy products and the source of these products.
- Drug history should be recorded, to include over-the-counter medications, prescription medications and any illicit substances.
- Immunisation status should be documented.
- Enquire about family history of illness.
- Occupational history should include exposure to chemicals/animals.
- Take a history of travel and recreational habits - including possible exposure to ticks and other vectors.
- Sexual history should be recorded.
Examination of the patient should include:
- Documentation of fever and exclusion of factitious fever (may be up to 10% of cases), which are essential early steps in the physical examination.
- Measuring the fever more than once and in the presence of another. Electronic thermometers give access to rapid and unequivocal documentation of fever.
- Diseases such as brucellosis, borreliosis and Hodgkin's disease tend to cause recurrent episodes of fever.
- Physical examination should be repeated daily while the patient is in hospital. Particularly, watch for:
- Lymph node enlargement
- Signs of arthritis
- New/changing cardiac murmurs
- Abdominal tenderness or rigidity
- Fundoscopic changes and neurological deficits
- The pattern of fever is usually of little help in the diagnosis. Correlation between fever patterns and specific diseases is weak. The exception is in tertian and quartan malaria, where the diagnosis is usually made within three weeks.
- FBC, erythrocyte sedimentation rate (ESR), U&Es, C-reactive protein (CRP), LFTs, antinuclear antibody (ANA), Rh factor and TFTs should be taken.
- Labelled white cell scan; in this investigation white cells are labelled extracorporeally and then re-injected into the patient. It is used to identify areas of sepsis. If the patient is neutropenic then donor white cells may be used.
False-positive scans may occur with haematomas and inflammatory disease. False negatives may occur in chronic sepsis.
- Blood cultures (preferably having been off antibiotics for several days) should be taken at differing times and from different sites. Culture for two weeks to detect slow-growing organisms and on special media if necessary.
- Culture urine, sputum, stool, CSF and morning gastric aspirates (if tuberculosis is suspected).
- CXR, abdominal CT scan and echocardiography (if endocarditis or atrial myxoma is suspected) should be considered.
- CT, intravenous pyelogram (IVP), MRI and positron emission tomography (PET) scanning all have a place in diagnosis.
- Hybrid F18-FDG Positron Emission Tomography/Computerised tomography (PET/CT) is a technique with high sensitivity and a relative non-specificity for malignancy, infection and inflammation. This makes it an ideal diagnostic tool for the investigation of PUO. Is should preferrably be used in the early work up of a patient, to guide more focussed investigations. The possibility of false positives should however be kept in mind.
- Invasive procedures for abnormal findings:
- Lumbar puncture for headache
- Skin biopsy for rash
- Lymph aspiration or biopsy for lymphadenopathy
- In an HIV-positive patient - bone marrow aspiration or biopsy
- Abnormal LFTs should prompt a liver biopsy (even if normal size)
- Laparoscopy or laparotomy is rarely necessary in the light of modern diagnostic techniques but may be required in patients who are deteriorating.
- Therapeutic trials if a diagnosis is strongly suspected - eg, tuberculosis, brucellosis.
This will depend on diagnosis. Empirical treatment has never been advocated in cases of PUO. There are, however, three important exceptions:
- Cases that meet criteria for culture-negative endocarditis.
- Cases suggestive of cryptic disseminated tuberculosis (or other granulomatous infections).
- Cases in which temporal arteritis (with vision loss) is suspected.
In an immunocompromised host
Any course of management should include consideration of risk:benefit for the patient. The patient may be clinically well apart from fever; however, broad-spectrum treatment may bring debilitating side-effects.
The disease course can be rapid, progressive and life-threatening:
- In neutropenic patients, fever may be the first and only sign of bacteraemia:
- Gram-negative organisms were mainly responsible in the past but now Gram-positive ones are most common isolates in many units, especially coagulase-negative staphylococci. However, about 70% of cultures will be negative despite rigorous investigations, and empirical treatment is required.
- In high swinging fever without any obvious focus or positive cultures, deep fungal infection is likely and, in fever persisting for >72 hours, an antifungal should be added. For many years, amphotericin B was the gold standard. However, better tolerated (but more expensive) options are now available including fluconazole, voriconazole and echinocandins. Amphotericin is recommended as an empirical antifungal treatment for patients with prolonged neutropenia.
- Take cultures and institute immediate antibiotic therapy before waiting for results:
- Commonly used regimens include antipseudomonal penicillin plus aminoglycoside - eg, piperacillin/gentamicin; third-generation cephalosporin - eg, ceftazidime or meropenem.
- These are very effective against common Gram-negative organisms but less so against Gram-positive ones which are now a more common problem. Reliably effective antibiotics against these are glycopeptides - eg, vancomycin. These are not generally added to empirical treatment because of their toxicity, cost and the fact that coagulase-negative staphylococci rarely cause death.
- Generally, vancomycin should be used only when blood culture results are known. Newer options have been developed but despite greater cure rates, they have not been shown to be more effective in reducing mortality.
- If a patient responds to initial treatment, continue for at least seven days and ideally until the neutrophil count reaches >0.5 x 109/L. If not, the therapy should be changed.
In non-neutropenic immunosuppressed patients, the situation is rarely immediately life-threatening and the diagnosis should be pursued as above.
Further reading & references
- Cunha BA; Fever of unknown origin: focused diagnostic approach based on clinical clues from the history, physical examination, and laboratory tests. Infect Dis Clin North Am. 2007 Dec;21(4):1137-87, xi.
- Petersdorf RG, Beeson PB; Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). 1961 Feb;40:1-30.
- Hayakawa K, Ramasamy B, Chandrasekar PH; Fever of unknown origin: an evidence-based review. Am J Med Sci. 2012 Oct;344(4):307-16.
- Durack DT, Street AC; Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35-51.
- Roth AR, Basello GM; Approach to the adult patient with fever of unknown origin. Am Fam Physician. 2003 Dec 1;68(11):2223-8.
- Tunkel A; Fever of Unkown Origin, Merck Manual, 2012
- PUO in late stage HIV:a system based approach; British HIV Association (BHIVA), 2009
- Mansueto P, Di Lorenzo G, Rizzo M, et al; Fever of unknown origin in a Mediterranean survey from a division of internal medicine: report of 91 cases during a 12-year-period (1991-2002). Intern Emerg Med. 2008 Feb 9.
- Ergonul O, Willke A, Azap A, et al; Revised definition of 'fever of unknown origin': limitations and opportunities. J Infect. 2005 Jan;50(1):1-5.
- Khoon W; Fever in Children, National University of Singapore, 2005
- Schmidt J, Warrington KJ; Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. Drugs Aging. 2011 Aug 1;28(8):651-66. doi: 10.2165/11592500-000000000-00000.
- Abdulkarim A; Pyrexia of Unknown Origin, 2008. (powerpoint presentation)
- Scagni P, Peisino MG, Bianchi M, et al; Kikuchi-Fujimoto disease is a rare cause of lymphadenopathy and fever of unknown origin in children: report of two cases and review of the literature. J Pediatr Hematol Oncol. 2005 Jun;27(6):337-40.
- Kapoor OP; PUO, Bombay Hospital Journal, Vol. 53, No. 4, 2011
- Zenone T; Fever of unknown origin in rheumatic diseases. Infect Dis Clin North Am. 2007 Dec;21(4):1115-35, x-xi.
- Feverish illness in children - Assessment and initial management in children younger than 5 years; NICE Guideline (May 2013)
- Balink H, Verberne HJ, Bennink RJ, et al; A Rationale for the Use of F18-FDG PET/CT in Fever and Inflammation of Unknown Origin. Int J Mol Imaging. 2012;2012:165080. doi: 10.1155/2012/165080. Epub 2012 Dec 17.
- Hao R, Yuan L, Kan Y, et al; Diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin: a meta-analysis. Nucl Med Commun. 2013 Jul;34(7):682-8. doi: 10.1097/MNM.0b013e328361cd0e.
- Mete B, Vanli E, Yemisen M, et al; The role of invasive and non-invasive procedures in diagnosing fever of unknown origin. Int J Med Sci. 2012;9(8):682-9. doi: 10.7150/ijms.4591. Epub 2012 Oct 1.
- Bryan CS, Ahuja D; Fever of unknown origin: is there a role for empiric therapy? Infect Dis Clin North Am. 2007 Dec;21(4):1213-20, xi.
- Penack O, Buchheidt D, Christopeit M, et al; Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Ann Oncol. 2011 May;22(5):1019-29. doi: 10.1093/annonc/mdq442. Epub 2010 Nov 1.
- Bohme A, Ruhnke M, Buchheidt D, et al; Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2009 Feb;88(2):97-110. doi: 10.1007/s00277-008-0622-5. Epub 2008 Oct 14.
- Noguchi S, Takahashi N, Ito M, et al; Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia. Int J Clin Oncol. 2012 Oct 18.
- Manji A, Lehrnbecher T, Dupuis LL, et al; A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer. 2012 Oct;20(10):2295-304. doi: 10.1007/s00520-011-1333-3. Epub 2011 Dec 6.
- van Hal SJ, Paterson DL; New Gram-positive antibiotics: better than vancomycin? Curr Opin Infect Dis. 2011 Dec;24(6):515-20. doi: 10.1097/QCO.0b013e32834ab1de.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
|Original Author: Dr Hayley Willacy||Current Version: Dr Laurence Knott||Peer Reviewer: Dr Helen Huins|
|Last Checked: 22/06/2013||Document ID: 586 Version: 24||© EMIS|